Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.
Profitability
This table compares Crinetics Pharmaceuticals and Xenetic Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Crinetics Pharmaceuticals | N/A | -35.09% | -32.04% |
| Xenetic Biosciences | -110.42% | -64.66% | -54.63% |
Valuation & Earnings
This table compares Crinetics Pharmaceuticals and Xenetic Biosciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crinetics Pharmaceuticals | $1.04 million | 4,556.54 | -$298.41 million | ($4.53) | -11.02 |
| Xenetic Biosciences | $2.50 million | 2.03 | -$3.96 million | ($2.05) | -1.08 |
Xenetic Biosciences has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Crinetics Pharmaceuticals and Xenetic Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crinetics Pharmaceuticals | 1 | 1 | 11 | 0 | 2.77 |
| Xenetic Biosciences | 1 | 1 | 0 | 0 | 1.50 |
Crinetics Pharmaceuticals currently has a consensus price target of $82.50, indicating a potential upside of 65.20%. Given Crinetics Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Xenetic Biosciences.
Risk & Volatility
Crinetics Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500.
Summary
Crinetics Pharmaceuticals beats Xenetic Biosciences on 8 of the 14 factors compared between the two stocks.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
